Healthy Volunteers
healthy people welcome
at San Francisco, California and other locations
study started
estimated completion
Principal Investigator
by Jacque Duncan, MD
Headshot of Jacque Duncan
Jacque Duncan



This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

Official Title

Qualification for Cone-Optogenetics (EyeConic)


In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.


Retinal Dystrophies, Cone-Optogenetics, Rod-cone Dystrophy, Cone-rod Dystrophy, Generalized retinal dystrophies, Inherited retinal disease, OCT


You can join if…


- Diagnosis of generalized IRD - Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye - Availability of macular optical coherence tomography (OCT) Inclusion Criteria (controls): - Normal ophthalmic findings - Availability of macular optical coherence tomography (OCT)

You CAN'T join if...


- Other eye diseases with a significant effect on vision or retinal structure - Extraocular disease affecting retinal structure such as neurodegenerative diseases


  • UCSF, Department of Ophthalmology accepting new patients
    San Francisco California 94158 United States
  • University of Pittsburgh, Department of Ophthalmology accepting new patients
    Pittsburgh Pennsylvania 15213 United States

Lead Scientist at UCSF

  • Jacque Duncan, MD
    Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.


accepting new patients
Start Date
Completion Date
University Hospital, Basel, Switzerland
Study Type
Expecting 1000 study participants
Last Updated